Rhythm Pharmaceuticals Income Statement (2016-2026) | RYTM

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026	Jun2026
Revenue & cost
Revenue (Quarter)	1.03M	1.82M	1.50M	9.07M	4.28M	-8.05M	11.47M	19.22M	22.50M	24.23M	25.97M	29.08M	33.25M	41.83M	32.70M	48.50M	51.30M	57.25M	60.11M	71.25M
Cost of Revenue (Quarter)	0.22M	0.24M	0.23M	0.38M	0.50M	1.03M	1.42M	2.24M	2.41M	3.23M	2.81M	2.95M	3.83M	3.79M	3.65M	5.54M	5.50M	4.80M	7.16M	8.93M
Gross Profit (Quarter)	0.81M	1.58M	1.27M	8.69M	3.79M	-9.08M	10.05M	16.98M	20.09M	21.00M	23.16M	26.13M	29.42M	38.04M	29.06M	42.96M	45.80M	52.45M	52.95M	62.32M
Operating items
Research & Development (Quarter)	27.54M	31.57M	32.51M	31.46M	21.12M	23.55M	37.95M	33.54M	33.57M	29.89M	128.66M	30.19M	37.93M	41.17M	36.97M	42.31M	46.03M	42.03M	41.73M	43.43M
Selling, General & Administrative (Quarter)	17.51M	21.00M	21.45M	22.33M	21.94M	26.32M	24.63M	30.05M	30.48M	32.37M	34.38M	36.41M	35.38M	38.13M	39.09M	45.95M	52.42M	57.48M	63.59M	67.45M
Other Operating Expenses (Quarter)	0.22M	0.24M	0.23M	0.38M	0.50M	1.03M	1.42M	2.24M	2.41M	3.23M	2.81M	2.95M	3.83M	3.79M	3.65M	5.54M	5.50M	4.80M	7.16M	8.93M
Operating Expenses (Quarter)	45.27M	52.81M	54.19M	54.16M	43.55M	50.89M	64.00M	65.83M	66.46M	65.50M	165.85M	69.56M	77.14M	83.08M	79.71M	93.80M	103.95M	104.32M	112.47M	119.81M
Operating Income (Quarter)	-44.24M	-50.99M	-52.69M	-45.10M	-39.27M	-42.10M	-52.53M	-46.60M	-43.95M	-41.27M	-139.89M	-40.48M	-43.88M	-41.26M	-47.00M	-45.30M	-52.65M	-47.06M	-52.36M	-48.55M
EBIT (Quarter)	-44.24M	-50.99M	-52.69M	-45.10M	-39.27M	-42.10M	-52.53M	-46.60M	-43.95M	-41.27M	-139.89M	-40.48M	-43.88M	-41.26M	-47.00M	-45.30M	-52.65M	-47.06M	-52.36M	-48.55M
Non-operating items
Interest & Investment Income (Quarter)	0.14M	0.13M	0.16M	0.27M	0.92M	3.04M	3.44M	3.22M	3.47M	3.82M	3.05M	4.10M	4.05M	3.52M	3.64M	3.24M	4.33M	4.08M	3.55M	3.22M
Other Non Operating Income (Quarter)			-0.23M	-0.13M	-0.37M	-0.42M	-0.03M	-0.02M	-0.16M	0.37M	0.52M	8.38M	1.09M	-6.66M	-0.64M	1.58M	0.27M	0.06M	-1.70M	1.02M
Non Operating Income (Quarter)	0.14M	0.13M	-0.07M	0.10M	-1.59M	-0.39M	0.35M	-0.10M	0.16M	-0.17M	-1.19M	8.70M	-0.10M	-2.13M	-2.41M	-1.00M	-0.14M	-0.47M	-2.73M	-0.30M
Net income details
EBT (Quarter)	-47.31M	-54.07M	-55.33M	-47.42M	-40.86M	-42.49M	-52.18M	-46.70M	-43.80M	-41.44M	-141.07M	-31.78M	-43.98M	-43.38M	-49.42M	-46.30M	-52.79M	-47.54M	-55.09M	-48.85M
Tax Provisions (Quarter)	-8.99M								0.37M	0.20M	0.30M	0.50M	-0.34M	-0.05M	0.10M	0.30M	0.11M	-0.03M	0.50M	0.44M
Profit After Tax (Quarter)	-35.11M	-42.87M	-52.76M	-45.00M	-40.86M	-42.49M	-52.18M	-46.70M	-44.16M	-41.63M	-141.37M	-32.26M	-43.64M	-43.29M	-50.83M	-46.63M	-52.90M	-47.51M	-55.64M	-50.65M
Income from Non-Controlling Interests (Quarter)															-0.01M				-0.54M	-0.36M
Income from Continuing Operations (Quarter)	-38.31M	-54.07M	-55.33M	-47.42M	-40.86M	-42.49M	-52.18M	-46.70M	-44.16M	-41.63M	-141.37M	-32.28M	-43.64M	-43.33M	-49.52M	-46.59M	-52.90M	-47.51M	-55.59M	-49.30M
Consolidated Net Income (Quarter)	-38.31M	-54.07M	-55.33M	-47.42M	-40.86M	-42.49M	-52.18M	-46.70M	-44.16M	-41.63M	-141.37M	-32.28M	-43.64M	-43.33M	-49.52M	-46.59M	-52.90M	-47.51M	-55.59M	-49.30M
Income towards Parent Company (Quarter)	-38.31M	-54.07M	-55.33M	-47.42M	-40.86M	-42.49M	-52.18M	-46.70M	-44.16M	-41.63M	-141.37M	-32.28M	-43.64M	-43.33M	-49.52M	-46.59M	-52.90M	-47.51M	-55.59M	-49.30M
Preferred Dividend Payments (Quarter)												1.30M	1.33M	1.34M	1.32M	1.35M	1.38M	1.33M	1.10M	1.06M
Net Income towards Common Stockholders (Quarter)	-38.31M	-54.07M	-55.33M	-47.42M	-40.86M	-42.49M	-52.18M	-46.70M	-44.16M	-41.63M	-141.37M	-33.56M	-44.97M	-44.63M	-50.82M	-47.98M	-54.28M	-48.84M	-56.74M	-50.36M
Additional items
EPS (Basic) (Quarter)	-0.76	-1.09	-1.10	-0.94	-0.79	-0.82	-0.92	-0.82	-0.76	-0.72	-2.35	-0.55	-0.73	-0.73	-0.81	-0.75	-0.82	-0.75	-0.83	-0.73
EPS (Diluted) (Quarter)	-0.76	-1.09	-1.10	-0.94	-0.79	-0.82	-0.92	-0.82	-0.76	-0.72	-2.35	-0.55	-0.73	-0.73	-0.81	-0.75	-0.82	-0.75	-0.83	-0.73
Shares Outstanding (Quarter)	50.25M	49.60M	50.33M	50.40M	51.40M	52.12M	56.71M	56.87M	57.87M	57.67M	60.14M	61.01M	61.22M	61.00M	63.06M	63.68M	66.26M	64.98M	67.97M	68.59M
Shares Outstanding (Diluted) (Quarter)	50.25M	49.60M	50.33M	50.40M	51.40M	52.12M	56.71M	56.87M	57.87M	57.67M	60.14M	61.01M	61.22M	61.00M	63.06M	63.68M	66.26M	64.98M	67.97M	68.59M
Shares Outstanding (Entity) (Quarter)	50.27M	50.28M	50.39M	50.45M	55.76M	56.61M	56.85M	56.90M	59.09M	59.43M	60.96M	61.10M	61.44M	62.39M	63.49M	63.91M	66.68M	67.21M	68.45M	68.82M
EBITDA (Quarter)	-44.24M	-50.99M	-52.69M	-45.10M	-39.27M	-42.10M	-52.53M	-46.60M	-43.95M	-41.27M	-139.89M	-40.48M	-43.88M	-41.26M	-47.00M	-45.30M	-52.65M	-47.06M	-52.36M	-48.55M
Interest Expenses (Quarter)	3.21M	3.21M	2.80M	2.60M	2.66M	3.01M	3.06M	3.30M	3.29M	4.55M	4.75M	4.60M	5.91M	5.45M	5.41M	5.82M	4.74M	4.62M	4.58M	4.54M
Tax Rate (Quarter)	19.01%								-0.84%	-0.47%	-0.21%	-1.57%	0.78%	0.12%	-0.20%	-0.65%	-0.21%	0.07%	-0.91%	-0.91%

Research Tools

Datasets

Plans

Developers

Rhythm Pharmaceuticals Income Statement (2016-2026) | RYTM

Research Tools

Datasets

Plans

Developers

Rhythm Pharmaceuticals Income Statement (2016-2026) | RYTM

Create an account

Sign In

Reset Password